Use the med and have asthma; don't use the med and no more than be able to walk across the room.
Anyone else dealing with this or have any answers?

A: No ... you do not have comnivent induced Asthma ... If your airway constraint (smooth muscle contraction and/or inflammation) is severe ... the drug will get going your airways and induce a wheeze if the bronchospasm / bronchoconstriction

Boehringer Ingelheim begins patient enrolment in phase III trial of once-daily ...

Boehringer Ingelheim has unquestioned to move the once-daily fixed-dose combination of tiotropium plus olodaterol into the TOviTO discontinue III trial program on the back of promising olodaterol phase III trial results, which will be published in the forthcoming... The trials are multi-centered, multi-national, randomised, coupled-blind, parallel group studies that will compare the efficacy and safeness of tiotropium plus olodaterol in fixed-dose combination with that of both mono-compounds (tiotropium TOnado 1 & 2 will be the first two focal studies to evaluate the safety and efficacy of the fixed-dose blend for the treatment of COPD patients, and are planned to involve 5000 patients (2500 each) at more than 500 contest sites in... It will investigate tiotropium plus olodaterol in a once-everyday fixed-dose combination for the treatment of Chronic Obstructive Pulmonary Cancer (COPD).

Source: pharmabiz.com

Boehringer Ingelheim enrols first patient in Phase III program for new once ...

safe keeping and efficacy of the fixed-dose combination for the treatment of. COPD patients, and are planned to betoken 5000 patients (2500 each) at. more than 500 trial sites in approaching 40 countries. trial program on the back of promising olodaterol Angle III trial. parallel group studies that will compare the efficacy and security of. tiotropium plus olodaterol in fixed-dose combination with that of both. plus olodaterol in a once-regular fixed-dose combination for the treatment. combination of tiotropium added olodaterol into the TOviTO Phase III. Boehringer Ingelheim today announced enrolment has commenced in its . TOviTO Slant gradually introduce III clinical trial program. Boehringer Ingelheim has decided to move the once-constantly fixed-dose. TOviTO program will be TOnado 1 and its replicate weigh, TOnado 2. Olodaterol is a novel once-daily long-acting ß2-agonist. (LABA) that Boehringer Ingelheim has developed as an standards partner to. tiotropium in COPD. Tiotropium - marketed under the brand name Spiriva® in COPD –. is a fancy-acting muscarinic antagonist (LAMA) that provides 24-hour. olodaterol’s implied to improve patients’ lives beyond optimal. Tiotropium is the most prescribed COPD opiate worldwide with more than 34. weeks, via Boehringer Ingelheim’s Respimat® Benign Mist™. The trials are multi-centered, multi-civil, randomised, double-blind,.

Source: PharmiWeb.com (press release)